Merck and Moderna’s vaccine shows promise during trials

Merck (known as MSD outside the US and Canada) and Moderna have announced positive results from the Phase 3 trial evaluating an investigational personalised mRNA cancer vaccine. T he vaccine, called Intismeran, was given in combination with Keytruda, an immunotherapy drug already used in cancer treatment. The readout represents the first successful Phase 3 trial for an individualised neoantigen…